Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $10.00 price target on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.33.

Immunic Trading Up 4.5%

NASDAQ IMUX opened at $0.94 on Friday. The stock has a market cap of $92.64 million, a P/E ratio of -1.00 and a beta of 1.44. The company’s fifty day simple moving average is $0.90 and its 200-day simple moving average is $0.92. Immunic has a 52 week low of $0.56 and a 52 week high of $1.73.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). On average, research analysts expect that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IMUX. Aberdeen Group plc increased its holdings in shares of Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after acquiring an additional 7,184,457 shares during the last quarter. Focus Partners Wealth boosted its holdings in Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after purchasing an additional 415,104 shares during the period. Jane Street Group LLC boosted its holdings in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after purchasing an additional 152,726 shares during the period. 683 Capital Management LLC increased its stake in Immunic by 28.6% during the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after purchasing an additional 479,846 shares during the period. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.